Eylea (aflibercept intravitreal) / Bayer, Regeneron - LARVOL DELTA

Multi-Center, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of 8 mg Aflibercept in Chinese Participants with Diabetic Macular Edema (ChiCTR) - P3 | N=322 | Recruiting | Sponsor: Bejing Tongren Hospital, Capital Medical Uniersity; Bejing Tongren Hospital, Capital Medical Uniersity

New P3 trial • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Molecular multiomics and multimodal imaging study of anti-VEGF preconditioning before minimally invasive vitrectomy in proliferative diabetic retinopathy (ChiCTR) - P4 | N=50 | Not yet recruiting | Sponsor: Foshan Second People's Hospital; Foshan Second People's Hospital

New P4 trial • Diabetic Retinopathy • Retinal Disorders • ICAM1

FAN: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P4 | N=70 | Completed | Sponsor: Medical University of Graz | Active, not recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Feb 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2024

Trial completion • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Dexamethasone intravitreal implant combines with VEGFR fusion protein versus VEGFR fusion protein alone for Diabetic Macular Edema: a multicentre, randomized, open-label clinical trial (ChiCTR) - P2 | N=98 | Completed | Sponsor: The Second Affiliated Hospital of Air Force Military Medical University,Chinese People’s Liberation Army; The Second Affiliated Hospital of Air Forc

New P2 trial • Diabetic Macular Edema • Ophthalmology

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 (clinicaltrials.gov) - P3 | N=400 | Active, not recruiting | Sponsor: EyePoint Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Nov 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Nov 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

QUASAR: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (clinicaltrials.gov) - P3 | N=892 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance. (PubMed, Graefes Arch Clin Exp Ophthalmol) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy (clinicaltrials.gov) - P4 | N=30 | Completed | Sponsor: Kim's Eye Hospital | Not yet recruiting ➔ Completed

Trial completion

Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy-A Case Report. (PubMed, Case Rep Ophthalmol Med) - "Management of CNV in PXE involves the prompt use of intravitreal anti-VEGF injections and vitrectomy with tissue plasminogen activator (tPA) for controlling CNV activity and submacular hemorrhage. Ophthalmologists should consider PXE in patients presenting with characteristic skin and eye findings and refer them for dermatological evaluation as necessary."

Journal • Age-related Macular Degeneration • Allergy • Cardiovascular • Gynecology • Hematological Disorders • Hypertension • Immunology • Ophthalmology • Retinal Disorders • Solid Tumor • Uterine Leiomyoma • Women's Health • ABCC6

Efficacy and Long-term Safety of CRISPR/Cas13 RNA-targeting Medicine in Mouse and Non-human Primate Models of Neovascular Age-related Macular Degeneration (ASGCT 2025) - "In monkeys, the incidence of grade IV lesions in the RM-102-treated groups was significantly reduced, comparable to 2 mg of Eylea administered intravitreally one week post-laser treatment (Fig... RM-102 effectively suppresses VEGFA expression and laser-induced CNV in NHPs, with excellent long-term safety. These results show that RM-102 is a promising treatment for nAMD and offer an option for non-responders to anti-VEGF therapies. Disease Focus of Abstract:Ophthalmic Diseases"

Preclinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Inhibition of Laser Induced Choroidal Neovascularization (LCNV) by Blocking Complement Activation Cascade Using AAV Vectors Carrying Complement Inhibition proteins (ASGCT 2025) - " C57BL/6J mice received bilateral intravitreal (IVT) injections of either Vehicle, Eylea (40 µg/mL), ABI-201 (sCD59+C3i fusion protein), ABI-202 (sCD59+C3i fusion protein), or AMI569 (C3i+sCD59) at a dose of 1.0E+09 vg/eye. This study demonstrates that complement inhibitors (C3i, sCD59, and their combinations with a C3i fusion protein) are comparable to anti-VEGF treatments like Eylea in reducing laser-induced retinal injury in a mouse LCNV model. These findings highlight the therapeutic potential of complement inhibitors to address inflammation, oxidative stress, and angiogenesis in retinal diseases such as wet AMD. By targeting complement activation, these therapies offer a broader mechanism of action beyond VEGF inhibition, providing new possibilities for standalone or combination therapies."

Age-related Macular Degeneration • Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab. (PubMed, Clin Ther) - "Interventions are needed to increase health literacy and access to IVI for at-risk, low-income populations. Future research should investigate patient and provider decision-making for anti-VEGF drug choice, which may have implications for cost-saving measures and policies."

Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Prospective evaluation of soluble CD14 as a biomarker following five aflibercept treatments in diabetic macular edema. (PubMed, Sci Rep) - "When the data were categorized into two groups based on the final visual outcome, patients with good final visual acuity had consistently lower levels of sCD14 at all visits. This study highlights sCD14 as a potential biomarker for assessing treatment response to aflibercept in DME."

Biomarker • Journal • Diabetic Macular Edema • Ophthalmology • CD14

Bayer confirms 2025 targets after solid start to the year (Bayer Press Release) - "Sales of prescription medicines (Pharmaceuticals) increased by 4.1 percent (Fx & portfolio adj.) to 4.548 billion euros. The division’s new products achieved significant gains, with growth rates of...86.6 percent (Fx & portfolio adj.) for Kerendia, for the treatment of chronic kidney disease associated with type 2 diabetes. Pharmaceuticals also posted continued sales growth for the ophthalmology drug Eylea, with an increase of 4.7 percent (Fx & portfolio adj.)....These positive effects were partially offset by declines for Xarelto in particular."

Commercial • Age-related Macular Degeneration • Coronary Artery Disease • Diabetes • Peripheral Arterial Disease • Pulmonary Embolism

Recurrence of Macular Edema in Branch Retinal Vein Occlusion - a Comparison of Aflibercept and Ranibizumab in a Randomized Trial. (PubMed, Ophthalmol Retina) - "Time to recurrence of ME in BRVO was significantly longer in patients treated with aflibercept compared to those receiving ranibizumab. A greater SFCT and diffSFCT at baseline was associated with a shorter time to edema recurrence, suggesting that these parameters could serve as predictive OCT biomarkers in BRVO."

Clinical • Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Catalpol Protects Against Retinal Ischemia Through Antioxidation, Anti-Ischemia, Downregulation of β-Catenin, VEGF, and Angiopoietin-2: In Vitro and In Vivo Studies. (PubMed, Int J Mol Sci) - "Intravitreous injections of catalpol (0.5 or 0.25 mM), Wnt inhibitor DKK1 (1 μg/4 μL), anti-VEGF Lucentis (40 μg/4 μL), or anti-VEGF Eylea (160 μg/4 μL) were administered to the rats' eyes 15 min before or after retinal ischemia. Moreover, ischemia-associated significant increases in apoptotic cells in the inner retina, inflammatory biomarker MCP-1, and ischemic indicator HIF-1α were significantly nullified by catalpol. Catalpol demonstrated antiapoptotic, anti-inflammatory, anti-ischemic (in vivo retinal ischemia or in vitro OGD), and antioxidative (in vitro) properties, counteracting retinal ischemia via suppressing upstream Wnt/β-catenin and inhibiting downstream HIF-1α, VEGF, and angiopoietin-2, together with its decreasing TUNEL apoptotic cell number and inflammatory MCP-1 concentration."

Journal • Preclinical • Cardiovascular • Ocular Inflammation • CTNNB1 • DKK1 • HIF1A

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (clinicaltrials.gov) - P2 | N=52 | Completed | Sponsor: Unity Biotechnology, Inc. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Bilateral Idiopathic Multifocal Pigment Epithelial Detachments: A Case Series and Review of Literature. (PubMed, Retina) - "IMPED should remain a diagnosis of exclusion, confirmed after sufficient follow-up demonstrating no progression. While our study implies a generally favorable prognosis, continuous monitoring is necessary to assess long-term risks, including potential complications such as the development of CNV and/or atrophy."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Comprehensive multi-omics and pharmacokinetics reveal sclareol's role in inhibiting ocular neovascularization. (PubMed, Phytomedicine) - "SCL is a promising orally administered natural compound for ocular neovascularization, offering a potential alternative or adjunctive therapy to existing anti-VEGF treatments."

Journal • PK/PD data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity • Wet Age-related Macular Degeneration

Tejas: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Ashvattha Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Nov 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Noninfectious Intraocular Inflammation After Intravitreal Aflibercept. (PubMed, JAMA Ophthalmol) - "This analysis in a clinical practice setting revealed a more frequent occurrence of IOI-associated AEs compared with previous clinical trials. All observed cases showed a mild IOI, which resolved under anti-inflammatory therapy without loss of BCVA."

Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

PULSOV: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Active, not recruiting ➔ Completed

Trial completion • Retinal Disorders • Retinal Vein Occlusion

Regeneron Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire) - "First quarter 2025 Dupixent global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024; First quarter 2025 EYLEA HD U.S. net sales increased 54% to $307 million versus first quarter 2024; total EYLEA HD and EYLEA U.S. net sales decreased 26% to $1.04 billion."

Sales • Age-related Macular Degeneration • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Diabetic Retinopathy • Macular Edema • Nasal Polyps • Wet Age-related Macular Degeneration